NRXPW
NRX Pharmaceuticals, Inc. Warrant$0.02-0.01 (-20.08%)Buys (12M)
0
$0.00
Sells (12M)
0
$0.00
Net Activity
Net Buyer
$0.00
Active Insiders
0
last 12 mo
NRXPW Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Javitt Jonathan C | Chairman and Chief Scientist | Buy | 40,000 | $1.17 | $46.8K | 84,634 |
| Sep 11, 2023 | Gorovitz Aaron | Buy | 35,000 | $0.32 | $11.2K | 105,000 | |
| Sep 11, 2023 | Hurvitz Chaim | Buy | 70,000 | $0.29 | $20.1K | 570,000 | |
| Aug 24, 2023 | Javitt Jonathan C | Chief Scientist | Buy | 100,000 | $0.33 | $33.0K | 446,332 |
| Aug 23, 2023 | Javitt Jonathan C | Chief Scientist | Buy | 200,000 | $0.32 | $64.4K | 346,332 |
| Dec 19, 2022 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | Buy | 30,000 | $1.10 | $33.0K | 46,337 |
| Dec 19, 2022 | Willard Stephen H | CHIEF EXECUTIVE OFFICER | Buy | 50,000 | $1.17 | $58.5K | 50,000 |
| Dec 9, 2022 | Javitt Jonathan C | Sell | 400,000 | $1.00 | $400.0K | 12,899,997 | |
| Dec 1, 2022 | Javitt Daniel C. | 10% Owner | Sell | 22,171 | $1.50 | $33.4K | 9,643,234 |
| Nov 29, 2022 | Flynn Patrick John | Buy | 9,250 | $1.25 | $11.5K | 40,209 | |
| Nov 28, 2022 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | Buy | 16,337 | $1.11 | $18.2K | 16,377 |
| Nov 21, 2022 | Hurvitz Chaim | Director | Buy | 500,000 | $1.03 | $514.9K | 500,000 |
| Nov 18, 2022 | Javitt Daniel C. | 10% Owner | Sell | 166,737 | $1.03 | $171.1K | 9,689,982 |
| Nov 15, 2022 | Javitt Daniel C. | 10% Owner | Sell | 49,200 | $1.01 | $49.5K | 9,823,701 |
| Aug 2, 2022 | Javitt Daniel C. | 10% Owner | Sell | 784,063 | $1.01 | $791.4K | 9,872,901 |
| Jun 7, 2022 | Javitt Daniel C. | 10% Owner | Sell | 445,712 | $0.68 | $303.9K | 12,859,080 |
| Jun 2, 2022 | Javitt Jonathan C | Chief Scientist | Buy | 100,000 | $58.00 | $5.80M | 146,332 |
| Nov 2, 2021 | Besthof Robert | Chief Comm. & Patient Officer | Sell | 40,000 | $11.76 | $470.4K | 23,710 |
| Nov 2, 2021 | Daigneault Alessandra | General Counsel & Secretary | Sell | 33,715 | $13.11 | $442.0K | 0 |
NRXPW Insider Buying Activity
The following table shows recent insider purchases of NRX Pharmaceuticals, Inc. Warrant (NRXPW) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Javitt Jonathan C | Chairman and Chief Scientist | Buy | 40,000 | $1.17 | $46.8K | 84,634 |
| Sep 11, 2023 | Gorovitz Aaron | Buy | 35,000 | $0.32 | $11.2K | 105,000 | |
| Sep 11, 2023 | Hurvitz Chaim | Buy | 70,000 | $0.29 | $20.1K | 570,000 | |
| Aug 24, 2023 | Javitt Jonathan C | Chief Scientist | Buy | 100,000 | $0.33 | $33.0K | 446,332 |
| Aug 23, 2023 | Javitt Jonathan C | Chief Scientist | Buy | 200,000 | $0.32 | $64.4K | 346,332 |
| Dec 19, 2022 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | Buy | 30,000 | $1.10 | $33.0K | 46,337 |
| Dec 19, 2022 | Willard Stephen H | CHIEF EXECUTIVE OFFICER | Buy | 50,000 | $1.17 | $58.5K | 50,000 |
| Nov 29, 2022 | Flynn Patrick John | Buy | 9,250 | $1.25 | $11.5K | 40,209 | |
| Nov 28, 2022 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | Buy | 16,337 | $1.11 | $18.2K | 16,377 |
| Nov 21, 2022 | Hurvitz Chaim | Director | Buy | 500,000 | $1.03 | $514.9K | 500,000 |
| Jun 2, 2022 | Javitt Jonathan C | Chief Scientist | Buy | 100,000 | $58.00 | $5.80M | 146,332 |
NRXPW Insider Selling Activity
The following table shows recent insider sales of NRX Pharmaceuticals, Inc. Warrant (NRXPW) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Javitt Jonathan C | Sell | 400,000 | $1.00 | $400.0K | 12,899,997 | |
| Dec 1, 2022 | Javitt Daniel C. | 10% Owner | Sell | 22,171 | $1.50 | $33.4K | 9,643,234 |
| Nov 18, 2022 | Javitt Daniel C. | 10% Owner | Sell | 166,737 | $1.03 | $171.1K | 9,689,982 |
| Nov 15, 2022 | Javitt Daniel C. | 10% Owner | Sell | 49,200 | $1.01 | $49.5K | 9,823,701 |
| Aug 2, 2022 | Javitt Daniel C. | 10% Owner | Sell | 784,063 | $1.01 | $791.4K | 9,872,901 |
| Jun 7, 2022 | Javitt Daniel C. | 10% Owner | Sell | 445,712 | $0.68 | $303.9K | 12,859,080 |
| Nov 2, 2021 | Besthof Robert | Chief Comm. & Patient Officer | Sell | 40,000 | $11.76 | $470.4K | 23,710 |
| Nov 2, 2021 | Daigneault Alessandra | General Counsel & Secretary | Sell | 33,715 | $13.11 | $442.0K | 0 |
NRXPW Insiders
Similar Stocks to NRXPW
SATA
Strive, Inc. Variable Rate Series A Perpetual Preferred Stock
$65.96B
BTSGU
BrightSpring Health Services, Inc. Tangible Equity Unit
$24.31B
STRD
Strategy Inc 10.00% Series A Perpetual Stride Preferred Stock
$21.06B
VLYPN
Valley National Bancorp 8.250% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series C
$14.53B
AGNCN
AGNC Investment Corp. Depositary Shares Each Representing a 1/1,000th Interest in a Share of 7 percent Series C Fixed-To-Floating Rate Cumulative Redeemable Preferred Stock
$8.80B
SLMBP
SLM Corporation Floating-Rate Non-Cumulative Series B
$6.75B
PFH
Prudential Financial, Inc. 4.125% Junior Subordinated Notes due 2060
$6.06B
VLYPP
Valley National Bancorp 6.25% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series A
$5.49B